David M. Barrett

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Hans Bitter, Tyler J. Reich, Frederic D Bushman, 2018, Nature Medicine.

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

D. Teachey, S. Grupp, B. Levine, 2017, Cytotherapy.

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

D. Teachey, S. Grupp, D. Porter, 2017, Critical care medicine.

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

S. Grupp, M. Kalos, C. June, 2016, Blood Cancer Journal.

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

D. Teachey, S. Grupp, D. Porter, 2016 .

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

M. Loh, D. Teachey, C. Sheen, 2012, Blood.

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.

Jason W. Moore, D. Teachey, S. Grupp, 2020, Blood advances.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

D. Teachey, M. Ruella, O. Shestova, 2024, Science Immunology.